



Global Drug Facility

*An innovative approach to
supplying anti-TB drugs*

Andrea de Lucia

**Team Leader, Regional Support and
Capacity Building**

2-3 April 2009



What is the GDF?



- An initiative of the Global Partnership to Stop TB (2002)
- Housed in WHO and managed by Stop TB Partnership secretariat
- Aims to *supply uninterrupted, quality assured, affordable TB medicines, where they are needed, when they are needed* as mandated by the **DOTS Strategy**
- More than a traditional procurement mechanism
 - A **bundled facility** (supply, TA in drug management, and quality assurance) **NOT just a procurement agent!**
- GDF has been ISO certified 9001:2000 since 2005



What will the GDF achieve?



- Supply treatments for 15 million patients by 2010 and for 25 million by 2015
- Improve the quality and reduce prices of anti-TB drugs worldwide
- Contribute to the achievement of the health MDGs
- Mitigate the emergence of anti-TB drug resistance
- Create successful model of cooperation/ coordinated to confront a global epidemic



What services does the GDF provide?



- **Grant Service** for countries and NGOs that are donor-dependent for some or all of their drug supply and wish to expand or strengthen DOTS programmes (first-line anti-TB drugs)
- **Direct Procurement (DP) Service** for countries, NGOs and donors wanting to buy 1st line (adult and paediatric) and diagnostic equipment for use in DOTS programmes or 2nd line anti-TB drugs for GLC approved projects;
- **Technical Assistance (TA) Service** whereby Grant and DP recipients receive TA through monitoring missions for in-country drug management (i.e. quantification, forecasting, patient kit training), staff training and support to improve (anti-TB drug) quality assurance



GDF Conditions of Support



- DOTS (expansion) Programme
- Anti-TB drugs and treatment should be free to patients
- Grant support to countries with GNI <3000 USD
- Agree to monitoring/technical assistance missions
- For grant countries, GDF should not replace government funding for anti-TB drugs (additionality)



How is the GDF organized?



STOP TB PARTNERSHIP SECRETARIAT

GDF SUBTEAM

Technical Review Committee

General Management

Quality Manager, ISO

Green Light Committee

Regional Portfolio Team

Procurement Team

Regional Support Officers (EMRO, SEARO, AFRO)



GDF Selection of Products



- GDF offers a **standardized** WHO-approved catalogue of anti-TB medicines and formulations (1st & 2nd line) and diagnostic equipment (drug-susceptible TB), which is designed to promote the products prioritized by the WHO Stop TB Department
- Standardization of **products** and **packaging** that contribute to **rationale drug use**, such as Fixed Dose Combination (FDC) tablets, blister packaging, child formulations and patient kits
- Helps in **avoiding mono-therapy**, thereby reducing the risks of developing **MDR TB**.



GDF Quantification




•GDF 1st line anti-TB drug spreadsheet & GLC 2nd Line drug estimation and request tool* – these tools help arrive at the following information (based on annual drug needs):

1. Quantities of each drug (including buffer % required)
2. Quantities of each drug by type of package
3. Cost of each drug requirements
4. Total cost of the annual drug needs

*soon to be available on PSM ToolBox



GDF Procurement Mechanism



Inventory Management & Use



- **GDF Order Management System**: Clients can track their orders online once it has been placed with suppliers
- **Annual missions** to GDF supported countries 4-6 months after order delivery. Checklist evaluates:
 - Case finding and treatment outcomes
 - TB programme and drug financing by fiscal year
 - Port clearance, warehouse storage, stock outs, ordering, etc.
 - GDF drugs registered or needing registration
 - Anti-TB drugs being manufactured in the country
 - Grant or DP drug requests for next year
 - Drug requirements, stock levels, types of packaging and cost
 - **Identifies technical assistance needs!!!**



GDF Capacity Building/TA Service



- **3 Regional Support Officers located in SEARO, EMRO and AFRO whose TORs include:**
 - Conducting annual missions and identify TA needs and necessary funding
 - Ad hoc training in using GDF Patient Kits and NTPs switching to FDCs
 - Regional or national drug management trainings for MOH staff or potential GDF DM consultants (~2-3/region/year).
 - Providing follow up to Technical Review Committee recommendations with countries and track possible drug stock outs.



GDF Capacity Building/TA Service



- TA needs in other regions (WPRO, EURO, AMRO) are brokered through partners (ie, MSH, independent consultants, etc)
- Funding for TA is taken from TGF grants, GDF grants, or NTP budgets.
- Over 60 annual missions/year and over 25 ad hoc TA missions/year



Challenges in Capacity Building in PSM



•Global Financial Sustainability

- Obtaining sustained commitment for funding anti-TB drugs

•Supply

- Supply of quality assured raw materials (API) for anti-TB drugs
- Too few suppliers of pre-qualified 2nd line drugs leading to monopoly positions, high prices, supply shortages, and non-standardized packaging
- Shelf-life of 1st line paediatric and 2nd line TB drugs can be short



What PSM challenges...(cont'd)



- In-country

- Improve and sustain in-country capacity for drug quantification/forecasting, financing, distribution and timely ordering of anti-TB drugs (how to target the right people for knowledge transfer)
- Weak national policies and regulatory framework for registration, procurement/tendering, quality assurance and rational use (strengthening NDRAs)
- Coordination with partners in conducting missions (ie, overburdening countries with visits)
- Evaluation of our TA and measuring impact



What PSM challenges...(cont'd)



- **GDF**

- How to monitor real-time stock levels in supported countries, which would alert us to stock-outs.
- Better national level forecasting would improve global forecasting to suppliers.



Thank you !
Andrea de Lucia deluciaa@who.int

www.stoptb.org/gdf

